{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T15:24:36Z","timestamp":1759073076128,"version":"3.40.3"},"publisher-location":"Cham","reference-count":73,"publisher":"Springer International Publishing","isbn-type":[{"type":"print","value":"9783030336783"},{"type":"electronic","value":"9783030336790"}],"license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019]]},"DOI":"10.1007\/164_2019_265","type":"book-chapter","created":{"date-parts":[[2019,8,26]],"date-time":"2019-08-26T07:02:44Z","timestamp":1566802964000},"page":"127-145","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Behavioral Pharmacology of Drugs Acting at Mu Opioid Receptors"],"prefix":"10.1007","author":[{"given":"Lisa R.","family":"Gerak","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David R.","family":"Maguire","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charles P.","family":"France","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,8,27]]},"reference":[{"key":"265_CR1","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1080\/03007995.2017.1334637","volume":"34","author":"GK Avetian","year":"2018","unstructured":"Avetian GK, Fiuty P, Mazzella S, Koppa D, Heye V, Hebbar P (2018) Use of naloxone nasal spray 4 mg in the community setting: a survey of use by community organizations. Curr Med Res Opin 34:573\u2013576","journal-title":"Curr Med Res Opin"},{"key":"265_CR2","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/0376-8716(85)90060-2","volume":"14","author":"RL Balster","year":"1985","unstructured":"Balster RL, Lukas SE (1985) Review of self-administration. Drug Alcohol Depend 14:249\u2013261","journal-title":"Drug Alcohol Depend"},{"key":"265_CR3","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1007\/s002130100821","volume":"158","author":"AC Barrett","year":"2001","unstructured":"Barrett AC, Cook CD, Terner JM, Craft RM, Picker MJ (2001) Importance of sex and relative efficacy at the mu opioid receptor in the development of tolerance and cross-tolerance to the antinociceptive effects of opioids. Psychopharmacology (Berl) 158:154\u2013164","journal-title":"Psychopharmacology (Berl)"},{"key":"265_CR4","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1097\/00004714-200012000-00002","volume":"20","author":"GJ Baylon","year":"2000","unstructured":"Baylon GJ, Kaplan HL, Somer G, Busto UE, Sellers EM (2000) Comparative abuse liability of intravenously administered remifentanil and fentanyl. J Clin Psychopharmacol 20:597\u2013606","journal-title":"J Clin Psychopharmacol"},{"key":"265_CR5","doi-asserted-by":"publisher","first-page":"2495","DOI":"10.1126\/science.286.5449.2495","volume":"286","author":"LM Bohn","year":"1999","unstructured":"Bohn LM, Lefkowitz RJ, Gainetdinov RR, Peppel K, Caron MG, Lin FT (1999) Enhanced morphine analgesia in mice lacking beta-arrestin 2. Science 286:2495\u20132498","journal-title":"Science"},{"key":"265_CR6","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1038\/35047086","volume":"408","author":"LM Bohn","year":"2000","unstructured":"Bohn LM, Gainetdinov RR, Lin FT, Lefkowitz RJ, Caron MG (2000) Mu-opioid receptor desensitization by beta-arrestin-2 determines morphine tolerance but not dependence. Nature 408:720\u2013723","journal-title":"Nature"},{"key":"265_CR7","first-page":"933","volume":"294","author":"JH Broadbear","year":"2000","unstructured":"Broadbear JH, Sumpter TL, Burke TF, Husbands SM, Lewis JW, Woods JH, Traynor JR (2000) Methocinnamox is a potent, long-lasting, and selective antagonist of morphine-mediated antinociception in the mouse: comparison with clocinnamox, \u03b2-funaltrexamine, and \u03b2-chlornaltrexamine. J Pharmacol Exp Ther 294:933\u2013940","journal-title":"J Pharmacol Exp Ther"},{"key":"265_CR8","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1111\/j.1365-2125.1982.tb01434.x","volume":"13","author":"R Bullingham","year":"1982","unstructured":"Bullingham R, McQuay H, Porter E, Allen H, Moore R (1982) Sublingual buprenorphine used postoperatively: ten hour plasma drug concentration analysis. Br J Clin Pharmacol 13:665\u2013673","journal-title":"Br J Clin Pharmacol"},{"key":"265_CR9","doi-asserted-by":"publisher","first-page":"10830","DOI":"10.1073\/pnas.1300393110","volume":"110","author":"NT Burford","year":"2013","unstructured":"Burford NT, Clark MJ, Wehrman TS, Gerritz SW, Banks M, O\u2019Connell J, Traynor JR, Alt A (2013) Discovery of positive allosteric modulators and silent allosteric modulators of the \u03bc-opioid receptor. Proc Natl Acad Sci U S A 110:10830\u201310835","journal-title":"Proc Natl Acad Sci U S A"},{"key":"265_CR10","unstructured":"Centers for Disease Control and Prevention (CDC) (2018) Annual surveillance report of drug-related risks and outcomes \u2013 United States. Surveillance special report. Centers for Disease Control and Prevention, U.S. Department of Health and Human Services. Published August 31, 2018. https:\/\/www.cdc.gov\/drugoverdose\/pdf\/pubs\/2018-cdc-drug-surveillance-report.pdf . Accessed 28 Sept 2018"},{"key":"265_CR11","first-page":"8","volume":"44","author":"Y Chen","year":"1993","unstructured":"Chen Y, Mestek A, Liu J, Hurley JA, Yu L (1993) Molecular cloning and functional expression of a mu-opioid receptor from rat brain. Mol Pharmacol 44:8\u201312","journal-title":"Mol Pharmacol"},{"key":"265_CR12","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1007\/s002130050956","volume":"143","author":"SD Comer","year":"1999","unstructured":"Comer SD, Collins ED, MacArthur RB, Fischman MW (1999) Comparison of intravenous and intranasal heroin self-administration by morphine-maintained humans. Psychopharmacology (Berl) 143:327\u2013338","journal-title":"Psychopharmacology (Berl)"},{"key":"265_CR13","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1124\/jpet.105.090423","volume":"315","author":"SD Comer","year":"2005","unstructured":"Comer SD, Sullivan MA, Walker EA (2005) Comparison of intravenous buprenorphine and methadone self-administration by recently detoxified heroin-dependent individuals. J Pharmacol Exp Ther 315:1320\u20131330","journal-title":"J Pharmacol Exp Ther"},{"key":"265_CR14","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/S0378-4274(98)00292-6","volume":"102\u2013103","author":"EJ Cone","year":"1998","unstructured":"Cone EJ (1998) Recent discoveries in pharmacokinetics of drugs of abuse. Toxicol Lett 102\u2013103:97\u2013101","journal-title":"Toxicol Lett"},{"key":"265_CR15","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1007\/s002130000453","volume":"130","author":"CD Cook","year":"2000","unstructured":"Cook CD, Barrett AC, Roach EL, Bowman JR, Picker MJ (2000) Sex-related differences in the antinociceptive effects of opioids: importance of rat genotype, nociceptive stimulus intensity, and efficacy at the mu opioid receptor. Psychopharmacology (Berl) 130:430\u2013442","journal-title":"Psychopharmacology (Berl)"},{"key":"265_CR16","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1097\/ALN.0b013e3181c38c25","volume":"112","author":"A Dahan","year":"2010","unstructured":"Dahan A, Aarts L, Smith TW (2010) Incidence, reversal, and prevention of opioid-induced respiratory depression. Anesthesiology 112:226\u2013238","journal-title":"Anesthesiology"},{"key":"265_CR17","first-page":"317","volume":"226","author":"LA Dykstra","year":"1983","unstructured":"Dykstra LA (1983) Behavioral effects of buprenorphine and diprenorphine under a multiple schedule of food presentation in squirrel monkeys. J Pharmacol Exp Ther 226:317\u2013323","journal-title":"J Pharmacol Exp Ther"},{"key":"265_CR18","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.1111\/j.1360-0443.1991.tb01754.x","volume":"86","author":"M Farr\u00e9","year":"1991","unstructured":"Farr\u00e9 M, Cam\u00ed J (1991) Pharmacokinetic considerations in abuse liability evaluation. Br J Addict 86:1601\u20131606","journal-title":"Br J Addict"},{"key":"265_CR19","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.neulet.2018.02.037","volume":"700","author":"M Filizola","year":"2019","unstructured":"Filizola M (2019) Insights from molecular dynamics simulations to exploit new trends for the development of improved opioid drugs. Neurosci Lett 700:50\u201355","journal-title":"Neurosci Lett"},{"key":"265_CR20","first-page":"652","volume":"230","author":"CP France","year":"1984","unstructured":"France CP, Jacobson AE, Woods JH (1984) Discriminative stimulus effects of reversible and irreversible opiate agonists: morphine, oxymorphazone and buprenorphine. J Pharmacol Exp Ther 230:652\u2013657","journal-title":"J Pharmacol Exp Ther"},{"key":"265_CR21","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.addbeh.2016.05.013","volume":"61","author":"AK Gatewood","year":"2016","unstructured":"Gatewood AK, Van Wert MJ, Andrada AP, Surkan PJ (2016) Academic physicians\u2019 and medical students\u2019 perceived barriers toward bystander administered naloxone as an overdose prevention strategy. Addict Behav 61:40\u201346","journal-title":"Addict Behav"},{"key":"265_CR22","first-page":"993","volume":"271","author":"LR Gerak","year":"1994","unstructured":"Gerak LR, Butelman ER, Woods JH, France CP (1994) Antinociceptive and respiratory effects of nalbuphine in rhesus monkeys. J Pharmacol Exp Ther 271:993\u2013999","journal-title":"J Pharmacol Exp Ther"},{"key":"265_CR23","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1007\/s002130050606","volume":"137","author":"LR Gerak","year":"1998","unstructured":"Gerak LR, Brandt MR, France CP (1998) Studies on benzodiazepines and opioids administered alone and in combination in rhesus monkeys: ventilation and drug discrimination. Psychopharmacology (Berl) 137:164\u2013174","journal-title":"Psychopharmacology (Berl)"},{"key":"265_CR24","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1007\/s00213-009-1471-1","volume":"204","author":"LR Gerak","year":"2009","unstructured":"Gerak LR, Galici R, France CP (2009) Self administration of heroin and cocaine in morphine-dependent and morphine-withdrawn rhesus monkeys. Psychopharmacology (Berl) 204:403\u2013411","journal-title":"Psychopharmacology (Berl)"},{"key":"265_CR25","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1124\/jpet.118.253286","volume":"368","author":"LR Gerak","year":"2019","unstructured":"Gerak LR, Maguire DR, Woods JH, Husbands SM, Disney A, France CP (2019) Reversal and prevention of the respiratory-depressant effects of heroin by the novel \u03bc opioid receptor antagonist methocinnamox in rhesus monkeys. J Pharmacol Exp Ther 368:229\u2013236","journal-title":"J Pharmacol Exp Ther"},{"key":"265_CR73","unstructured":"Gerak LR, Minervini V, Latham E, Ghodrati S, Lillis KV, Wooden J, Disney A, Husbands SM, France CP (under review) Methocinnamox (MCAM) produces long-lasting antagonism of the behavioral effects of \u03bc opioid receptor agonists but not prolonged precipitated withdrawal in rats. J Pharmacol Exp Ther"},{"key":"265_CR26","doi-asserted-by":"crossref","first-page":"15117","DOI":"10.1016\/S0021-9258(18)95710-8","volume":"260","author":"TL Gioannini","year":"1985","unstructured":"Gioannini TL, Howard AD, Hiller JM, Simon EJ (1985) Purification of an active opioid-binding protein from bovine striatum. J Biol Chem 260:15117\u201315121","journal-title":"J Biol Chem"},{"key":"265_CR27","first-page":"296","volume":"235","author":"DE Gmerek","year":"1985","unstructured":"Gmerek DE, Woods JH (1985) Effects of beta-funaltrexamine in normal and morphine-dependent rhesus monkeys: observational studies. J Pharmacol Exp Ther 235:296\u2013301","journal-title":"J Pharmacol Exp Ther"},{"key":"265_CR28","first-page":"295","volume-title":"Opiates and endogenous peptides","author":"J Hambrook","year":"1976","unstructured":"Hambrook J, Rance M (1976) The interaction of buprenorphine with the opiate receptor: lipophilicity as a determining factor in drug-receptor kinetics. In: Kosterlitz H (ed) Opiates and endogenous peptides. North Holland, Amsterdam, pp 295\u2013301"},{"key":"265_CR29","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1111\/j.1476-5381.1986.tb16260.x","volume":"88","author":"AG Hayes","year":"1986","unstructured":"Hayes AG, Skingle M, Tyers MB (1986) Reversal by beta-funaltrexamine of the antinociceptive effect of opioid agonists in the rat. Br J Pharmacol 88:867\u2013872","journal-title":"Br J Pharmacol"},{"key":"265_CR30","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1111\/add.14180","volume":"113","author":"BP Jarvis","year":"2018","unstructured":"Jarvis BP, Holtyn AF, Subramaniam S, Tompkins DA, Oga EA, Bigelow GE, Silverman K (2018) Extended-release injectable naltrexone for opioid use disorder: a systematic review. Addiction 113:1188\u20131209","journal-title":"Addiction"},{"key":"265_CR31","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/j.pbb.2014.04.012","volume":"122","author":"JD Jones","year":"2014","unstructured":"Jones JD, Madera G, Comer SD (2014) The reinforcing and subjective effect of intravenous and intranasal buprenorphine in heroin users. Pharmacol Biochem Behav 122:299\u2013306","journal-title":"Pharmacol Biochem Behav"},{"key":"265_CR32","doi-asserted-by":"publisher","first-page":"1.2.1","DOI":"10.1002\/0471141755.ph0102s41","volume":"41","author":"T Kenakin","year":"2008","unstructured":"Kenakin T (2008) Receptor theory. Curr Protoc Pharmacol 41:1.2.1\u20131.2.28","journal-title":"Curr Protoc Pharmacol"},{"key":"265_CR33","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/S0379-0738(01)00454-6","volume":"121","author":"P Kintz","year":"2001","unstructured":"Kintz P (2001) Deaths involving buprenorphine: a compendium of French cases. Foren Sci Int 121:65\u201369","journal-title":"Foren Sci Int"},{"key":"265_CR34","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/S0014-2999(00)00039-X","volume":"391","author":"S Kishioka","year":"2000","unstructured":"Kishioka S, Paronis CA, Lewis JW, Woods JH (2000) Buprenorphine and methoclocinnamox: agonist and antagonist effects on respiratory function in rhesus monkeys. Eur J Pharmacol 391:289\u2013297","journal-title":"Eur J Pharmacol"},{"key":"265_CR35","doi-asserted-by":"publisher","first-page":"L463","DOI":"10.1016\/0024-3205(94)90138-4","volume":"54","author":"RJ Knapp","year":"1994","unstructured":"Knapp RJ, Malatynska E, Fang L, Li X, Babin E, Nguyen M, Santoro G, Varga EV, Hruby VJ, Roeske WR (1994) Identification of a human delta opioid receptor: cloning and expression. Life Sci 54:L463\u2013L469","journal-title":"Life Sci"},{"key":"265_CR36","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1124\/jpet.114.216648","volume":"351","author":"DR Maguire","year":"2014","unstructured":"Maguire DR, France CP (2014) Impact of efficacy at the mu-opioid receptor on antinociceptive effects of combinations of mu-opioid receptor agonists and cannabinoid receptor agonists. J Pharmacol Ther Exp 351:383\u2013389","journal-title":"J Pharmacol Ther Exp"},{"key":"265_CR37","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1097\/FBP.0000000000000192","volume":"27","author":"DR Maguire","year":"2016","unstructured":"Maguire DR, France CP (2016) Effects of daily delta-9-tetrahydrocannabinol treatment on heroin self-administration in rhesus monkeys. Behav Pharmacol 27:249\u2013257","journal-title":"Behav Pharmacol"},{"key":"265_CR38","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1124\/jpet.118.252353","volume":"368","author":"DR Maguire","year":"2019","unstructured":"Maguire DR, Gerak LR, Woods JH, Husbands SM, Disney A, France CP (2019) Long-lasting effects of methocinnamox on heroin self-administration in rhesus monkeys. J Pharmacol Exp Ther 368:88\u201399","journal-title":"J Pharmacol Exp Ther"},{"key":"265_CR39","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.ejphar.2012.04.001","volume":"685","author":"HT Maguma","year":"2012","unstructured":"Maguma HT, Dewey WL, Akbarali HI (2012) Differences in the characteristics of tolerance to \u03bc-opioid receptor agonists in the colon from wild type and \u03b2-arrestin2 knockout mice. Eur J Pharmacol 685:133\u2013140","journal-title":"Eur J Pharmacol"},{"key":"265_CR40","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.jen.2010.11.013","volume":"37","author":"HA Martin","year":"2011","unstructured":"Martin HA (2011) The possible consequences of combining lorazepam and buprenorphine\/naloxone: a case review. J Emerg Nurs 37:200\u2013202","journal-title":"J Emerg Nurs"},{"key":"265_CR41","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/0091-3057(81)90180-5","volume":"15","author":"NK Mello","year":"1981","unstructured":"Mello NK, Bree MP, Mendelson JH (1981a) Buprenorphine self-administration by rhesus monkey. Pharmacol Biochem Behav 15:215\u2013225","journal-title":"Pharmacol Biochem Behav"},{"key":"265_CR42","first-page":"45","volume":"216","author":"NK Mello","year":"1981","unstructured":"Mello NK, Mendelson JH, Kuehnle JC, Sellers MS (1981b) Operant analysis of human heroin self-administration and the effects of naltrexone. J Pharmacol Exp Ther 216:45\u201354","journal-title":"J Pharmacol Exp Ther"},{"key":"265_CR43","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/0376-8716(88)90053-1","volume":"21","author":"NK Mello","year":"1988","unstructured":"Mello NK, Lukas SE, Bree MP, Mendelson JH (1988) Progressive ratio performance maintained by buprenorphine, heroin and methadone in Macaque monkeys. Drug Alcohol Depend 21:81\u201397","journal-title":"Drug Alcohol Depend"},{"key":"265_CR44","doi-asserted-by":"publisher","first-page":"9954","DOI":"10.1073\/pnas.90.21.9954","volume":"90","author":"F Meng","year":"1993","unstructured":"Meng F, Xie GX, Thompson RC, Mansour A, Goldstein A, Watson SJ, Akil H (1993) Cloning and pharmacological characterization of a rat kappa opioid receptor. Proc Natl Acad Sci U S A 90:9954\u20139958","journal-title":"Proc Natl Acad Sci U S A"},{"key":"265_CR45","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1016\/j.tips.2018.08.007","volume":"39","author":"SS Negus","year":"2018","unstructured":"Negus SS, Freeman KB (2018) Abuse potential of biased mu opioid receptor agonists. Trends Pharmacol Sci 39:916\u2013919","journal-title":"Trends Pharmacol Sci"},{"key":"265_CR46","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.brainres.2005.07.060","volume":"1058","author":"EM Peckham","year":"2005","unstructured":"Peckham EM, Barkley LM, Divin MF, Cicero TJ, Traynor JR (2005) Comparison of the antinociceptive effect of acute morphine in female and male Sprague-Dawley rats using the long-lasting mu-antagonist methocinnamox. Brain Res 1058:137\u2013147","journal-title":"Brain Res"},{"key":"265_CR47","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1007\/s00414-010-0449-1","volume":"124","author":"A-L Pelissier-Alicot","year":"2010","unstructured":"Pelissier-Alicot A-L, Sastre C, Baillif-Couniou V, Gaulier J-M, Kintz P, Kuhlmann E, Perich P, Bartoli C, Piercecchi-Marti M-D, Leonetti G (2010) Buprenorphine-related deaths: unusual forensic situations. Int J Leg Med 124:647\u2013651","journal-title":"Int J Leg Med"},{"key":"265_CR48","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1126\/science.182.4119.1359","volume":"182","author":"CB Pert","year":"1973","unstructured":"Pert CB, Pasternak GW, Snyder SH (1973) Opiate agonists and antagonists discriminated by receptor binding in brain. Science 182:1359\u20131361","journal-title":"Science"},{"key":"265_CR49","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1111\/j.1360-0443.2004.00790.x","volume":"99","author":"S Pirnay","year":"2004","unstructured":"Pirnay S, Borron SW, Giudicelli CP, Tourneau J, Baud FJ, Ricordel I (2004) A critical review of the causes of death among post-mortem toxicological investigations: analysis of 34 buprenorphine-associated and 35 methadone-associated deaths. Addiction 99:978\u2013988","journal-title":"Addiction"},{"key":"265_CR50","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1124\/jpet.105.087254","volume":"314","author":"KM Raehal","year":"2005","unstructured":"Raehal KM, Walker JM, Bohn LM (2005) Morphine side effects in beta-arrestin 2 knockout mice. J Pharmacol Exp Ther 314:1195\u20131201","journal-title":"J Pharmacol Exp Ther"},{"key":"265_CR51","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1176\/ajp.155.3.447-b","volume":"155","author":"M Reynaud","year":"1998","unstructured":"Reynaud M, Tracqui A, Petit G, Potard D, Courty P (1998) Six deaths linked to misuse of buprenorphine-benzodiazepine combinations. Am J Psychiatry 155:448\u2013449","journal-title":"Am J Psychiatry"},{"key":"265_CR52","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1124\/jpet.106.113167","volume":"320","author":"RB Rothman","year":"2007","unstructured":"Rothman RB, Murphy DL, Xu H, Godin JA, Dersch CM, Partilla JS, Tidgewell K, Schimidt M, Prisinzano TE (2007) Salvinorin A: allosteric interactions at the \u03bc-opioid receptor. J Pharmacol Exp Ther 320:801\u2013810","journal-title":"J Pharmacol Exp Ther"},{"key":"265_CR53","first-page":"32","volume":"12","author":"RA Sansone","year":"2015","unstructured":"Sansone RA, Sansone LA (2015) Buprenorphine treatment for narcotic addiction: not without risks. Innov Clin Neurosci 12:32\u201336","journal-title":"Innov Clin Neurosci"},{"key":"265_CR54","doi-asserted-by":"publisher","first-page":"1947","DOI":"10.1073\/pnas.70.7.1947","volume":"70","author":"EJ Simon","year":"1973","unstructured":"Simon EJ, Hiller JM, Edelman I (1973) Stereospecific binding of the potent narcotic analgesic [3H]etorphine to rat-brain homogenate. Proc Natl Acad Sci 70:1947\u20131949","journal-title":"Proc Natl Acad Sci"},{"key":"265_CR55","doi-asserted-by":"crossref","first-page":"247","DOI":"10.31887\/DCNS.2017.19.3\/rspanagel","volume":"19","author":"R Spanagel","year":"2017","unstructured":"Spanagel R (2017) Animal models of addiction. Dialogues Clin Neurosci 19:247\u2013258","journal-title":"Dialogues Clin Neurosci"},{"key":"265_CR56","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.coph.2016.11.007","volume":"32","author":"ER Suida","year":"2017","unstructured":"Suida ER, Carr R, Rominger DH, Violin JD (2017) Biased mu-opioid receptor ligands: a promising new generation of pain therapeutics. Curr Opin Pharmacol 32:77\u201384","journal-title":"Curr Opin Pharmacol"},{"key":"265_CR57","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1111\/j.1600-0773.1973.tb01477.x","volume":"32","author":"L Terenius","year":"1973","unstructured":"Terenius L (1973) Stereospecific interaction between narcotic analgesics and a synaptic plasma membrane fraction of rat cerebral cortex. Acta Pharmacol Toxicol 32:317\u2013320","journal-title":"Acta Pharmacol Toxicol"},{"key":"265_CR58","doi-asserted-by":"publisher","first-page":"107","DOI":"10.15585\/mm6604a4","volume":"66","author":"AJ Tomassoni","year":"2017","unstructured":"Tomassoni AJ, Hawk KF, Jubanyik K, Nogee DP, Durant T, Lynch KL, Patel R, Dinh D, Ulrich A, D\u2019Onofrio GD (2017) Multiple fentanyl overdoses \u2013 New Haven, Connecticut, June 23, 2016. MMWR Morb Mortal Wkly Rep 66:107\u2013111","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"265_CR59","doi-asserted-by":"publisher","first-page":"2514","DOI":"10.1038\/s41386-018-0225-3","volume":"43","author":"RJ Valentino","year":"2018","unstructured":"Valentino RJ, Volkow ND (2018) Untangling the complexity of opioid receptor function. Neuropsychopharmacology 43:2514\u20132520","journal-title":"Neuropsychopharmacology"},{"key":"265_CR60","first-page":"697","volume":"286","author":"JA Vivian","year":"1998","unstructured":"Vivian JA, Kishioka S, Butelman ER, Broadbear J, Lee KO, Woods JH (1998) Analgesic, respiratory and heart rate effects of cannabinoid and opioid agonists in rhesus monkeys: antagonist effects of SR 141716A. J Pharmacol Exp Ther 286:697\u2013703","journal-title":"J Pharmacol Exp Ther"},{"key":"265_CR61","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1111\/j.1360-0443.1991.tb01745.x","volume":"12","author":"F Vocci","year":"1991","unstructured":"Vocci F (1991) The necessity and utility of abuse liability testing in human subjects. Br J Addict 12:1537\u20131542","journal-title":"Br J Addict"},{"key":"265_CR62","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1056\/NEJMra1507771","volume":"374","author":"ND Volkow","year":"2016","unstructured":"Volkow ND, McLellan AT (2016) Opioid abuse in chronic pain \u2013 misconceptions and mitigation strategies. N Engl J Med 374:1253\u20131256","journal-title":"N Engl J Med"},{"key":"265_CR63","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1146\/annurev.biochem.73.011303.073940","volume":"73","author":"M Waldhoer","year":"2004","unstructured":"Waldhoer M, Bartlett SE, Whistler JL (2004) Opioid receptors. Annu Rev Biochem 73:953\u2013990","journal-title":"Annu Rev Biochem"},{"key":"265_CR64","first-page":"959","volume":"271","author":"EA Walker","year":"1994","unstructured":"Walker EA, Makhay MM, House JD, Young AM (1994) In vivo apparent pA2 analysis for naltrexone antagonism of discriminative stimulus and analgesic effects of opiate agonists in rats. J Pharmacol Exp Ther 271:959\u2013968","journal-title":"J Pharmacol Exp Ther"},{"key":"265_CR65","first-page":"1345","volume":"273","author":"EA Walker","year":"1995","unstructured":"Walker EA, Zernig G, Woods JH (1995) Buprenorphine antagonism of mu opioids in the rhesus monkey tail-withdrawal procedure. J Pharmacol Exp Ther 273:1345\u20131352","journal-title":"J Pharmacol Exp Ther"},{"key":"265_CR66","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1038\/clpt.1994.71","volume":"55","author":"SL Walsh","year":"1994","unstructured":"Walsh SL, Preston KL, Stitzer ML, Cosa EJ, Bigelow GE (1994) Clinical pharmacology of buprenorphine: ceiling effects at high doses. Clin Pharmacol Ther 55:569\u2013580","journal-title":"Clin Pharmacol Ther"},{"key":"265_CR67","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1177\/2042098614564776","volume":"6","author":"DP Wermeling","year":"2015","unstructured":"Wermeling DP (2015) Review of naloxone safety for opioid overdose: practical considerations for new technology and expanded public access. Ther Adv Drug Saf 6:20\u201331","journal-title":"Ther Adv Drug Saf"},{"key":"265_CR68","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/0376-8716(91)90044-Y","volume":"29","author":"B Wolf","year":"1991","unstructured":"Wolf B, Griffiths RR (1991) Physical dependence on benzodiazepines: differences within the class. Drug Alcohol Depend 29:153\u2013156","journal-title":"Drug Alcohol Depend"},{"key":"265_CR69","first-page":"795","volume":"257","author":"AM Young","year":"1991","unstructured":"Young AM, Kapitsopoulos G, Makhay MM (1991) Tolerance to morphine-like stimulus effects of mu opioid agonists. J Pharmacol Exp Ther 257:795\u2013805","journal-title":"J Pharmacol Exp Ther"},{"key":"265_CR70","first-page":"246","volume":"261","author":"AM Young","year":"1992","unstructured":"Young AM, Masaki MA, Geula C (1992) Discriminative stimulus effects of morphine: effects of training dose on agonist and antagonist effects of mu opioids. J Pharmacol Exp Ther 261:246\u2013257","journal-title":"J Pharmacol Exp Ther"},{"key":"265_CR71","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.drugalcdep.2018.08.002","volume":"192","author":"CA Zamarripa","year":"2018","unstructured":"Zamarripa CA, Edwards SR, Qureshi HN, Yi JN, Blough BE, Freeman KB (2018) The G-protein biased mu-opioid agonist, TRV130, produces reinforcing and antinociceptive effects that are comparable to oxycodone in rats. Drug Alcohol Depend 192:158\u2013162","journal-title":"Drug Alcohol Depend"},{"key":"265_CR72","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1007\/s002130050035","volume":"148","author":"L Zhang","year":"2000","unstructured":"Zhang L, Walker EA, Sutherland J 2nd, Young AM (2000) Discriminative stimulus effects of two doses of fentanyl in rats: pharmacological selectivity and effect of training dose on agonist and antagonist effects of mu opioids. Psychopharmacology (Berl) 148:136\u2013145","journal-title":"Psychopharmacology (Berl)"}],"container-title":["Handbook of Experimental Pharmacology","Substance Use Disorders"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/164_2019_265","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,17]],"date-time":"2021-01-17T11:01:58Z","timestamp":1610881318000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/164_2019_265"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019]]},"ISBN":["9783030336783","9783030336790"],"references-count":73,"URL":"https:\/\/doi.org\/10.1007\/164_2019_265","relation":{},"ISSN":["0171-2004","1865-0325"],"issn-type":[{"type":"print","value":"0171-2004"},{"type":"electronic","value":"1865-0325"}],"subject":[],"published":{"date-parts":[[2019]]},"assertion":[{"value":"27 August 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}